18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours

Area of Science:

• Oncology
• Medical Imaging
• Nuclear Medicine

Background:

• Current solid tumor treatment response guidelines rely on computed tomography (CT) criteria.
• Emerging functional imaging techniques offer new ways to assess cancer therapy effectiveness.
• FDG-PET scanning measures metabolic activity, providing a different perspective than anatomical imaging.

Purpose of the Study:

• To provide an overview of data on response prediction in solid tumors using positron emission tomography (PET).
• To evaluate the potential of FDG-PET scanning in assessing early treatment response.
• To highlight the advantages and limitations of FDG-PET in cancer therapy evaluation.

Main Methods:

• Review of existing studies on FDG-PET for response prediction in solid tumors.
• Comparison of FDG-PET performance against traditional CT criteria.
• Analysis of FDG-PET's utility in specific cancer types like lung, breast, and esophageal cancer.

Main Results:

• FDG-PET scanning can predict treatment response earlier than CT criteria, particularly in the neoadjuvant setting.
• Studies indicate FDG-PET may outperform CT in assessing treatment response, despite lower specificity.
• Early response prediction by FDG-PET could lead to reduced ineffective therapies, costs, and patient toxicity.

Conclusions:

• FDG-PET scanning shows significant potential for early cancer therapy response prediction in solid tumors.
• Wider adoption is hindered by the lack of established response thresholds and large-scale validation studies.
• Further research is crucial to integrate FDG-PET into standard clinical response guidelines for improved patient management.